Study S002708

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT05214573
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 386301
Start: 2021-12-01
Primary completion: 2023-09-30
Lead sponsor: Mayo Clinic
Conditions: Type 2 Diabetes; Cardiac Disease
Interventions: DRUG:Glucagon like peptide 1 receptor agonist; DRUG:Sodium-glucose cotransporter 2 inhibitor; DRUG:Dipeptidyl Peptidase 4 Inhibitor; DRUG:Sulfonylurea
Results posted: TRUE

Registered primary outcomes

3-point Major Adverse Cardiovascular Event (MACE) [Retrospective Data between 1/1/2014 - 12/31/2022, up to 8 years, collected over a 2-year period]
Expanded Major Adverse Cardiovascular Events (MACE) and Its Components [Retrospective Data between 1/1/2014 - 12/31/2022, up to 8 years, collected over a 2-year period]
Patient Preferences for Second-line Type 2 Diabetes Medication Treatment Outcomes [1 hour]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0001594	Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk. Neumiller JJ, Clinical journal of the American Society of Nephrology : CJASN	2025	Nonrandomized study	PMID 39729347 DOI	cites ClinicalTrials.gov:NCT05214573; registry reference DERIVED:39729347
R0005811	GLP-1RA Use and Thyroid Cancer Risk. Brito JP, JAMA otolaryngology-- head & neck surgery	2025	Nonrandomized study	PMID 39847346 DOI	cites ClinicalTrials.gov:NCT05214573; registry reference DERIVED:39847346
R0006107	Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk. McCoy RG, Nature cardiovascular research	2024	Nonrandomized study	PMID 38846711 DOI	cites ClinicalTrials.gov:NCT05214573; registry reference DERIVED:38846711